Coronavirus information

Visitor restrictions, information for patients and more.

View coronavirus information

FOI 0366 2019/20 Metastatic Differentiated Thyroid Cancer Treatment

Home > FOI Requests > Other > FOI 0366 2019/20 Metastatic Differentiated Thyroid Cancer Treatment

October 18, 2019

Last updated: October 18, 2019

Freedom of Information Request: 0366 2019/20

  1. In the past 12 months, how many patients with metastatic differentiated thyroid (refractory to radioactive iodine) cancer were treated with:

    Axitinib
    Cabozantinib
    Lenvantinib
    Pazopanib
    Sorafenib
    Sunitinib
    Vandetanib

    2. In the past 12 months, how many metastatic Renal Cell Carcinoma patients were treated with:

    Sunitinib
    Pazopanib
    Everolimus
    Temsirolimus
    Cabozantinib
    Nivolumab
    Axinitib
    Nivolumab + Ipilimumab
    Lenvantinib + Everolimus
    Tivozanib
    Pembrolizumab + Axitinib
    Avelumab + Axitinib

    3. In the past 12 months, how many metastatic Hepatic Cell Carcinoma patients were treated with:

    Bevacizumab
    Cisplatin
    Doxorubicin
    Everolimus
    Lapatinib
    Lenvantinib
    Regorafenib
    Sorafenib
    Sunitinib

Please see attached document

FOI 0366

Thinking of going to Accident and Emergency but not sure if you need to? Try our handy symptom checker.

Try ask A&E

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.